Russel Metals Price Target Raised to $68 at RBC

RBC Capital Markets raised its price target on Russel Metals (RUS.TO) to $68 from $63.

Analyst James McGarragle maintained an Outperform rating on shares of the Canadian metals distribution and processing company.

The analyst said Russel shares traded up 24% in Q2, a strong share price performance that he does not believe is factored into consensus numbers, "and we therefore view our estimate as representing significant upside versus what is being built into street estimates."

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Update: BofA Downgrades Doximity to Underperform From Buy, Cuts Price Target to $20 From $38

(Updates with the analyst's commentary.)BofA Securities downgraded Doximity (DOCS) to underperform rating from buy and cut its price target to $20 from $38.The brokerage attributes the downgrade to "limited clarity" on near-term revenue/margins movement and "execution risks" from the company's pivot to artificial intelligence (AI).While BofA believes Doximity is "making the right strategic investments," the brokerage has "some concerns" over the firm's capability "to grow its current allocations" and to compete in the AI space.Doximity has an average rating of overweight and mean price target of $24.27, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $20.63, Change: $-0.25, Percent Change: -1.20%

$DOCS

Russel Metals Price Target Raised to $68 at RBC

Related Articles

Update: BofA Downgrades Doximity to Underperform From Buy, Cuts Price Target to $20 From $38

BofA Securities Initiates Quantinuum at Buy With $100 Price Target

BTIG Downgrades Theravance Biopharma to Neutral From Buy